Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Revenue (2022 - 2024)

Adial Pharmaceuticals' Revenue history spans 3 years, with the latest figure at -$1.0 for Q2 2024.

  • For Q2 2024, Revenue rose 100.0% year-over-year to -$1.0; the TTM value through Dec 2024 reached $164657.0, up 815.62%, while the annual FY2021 figure was $46494.0, 1759.76% up from the prior year.
  • Revenue for Q2 2024 was -$1.0 at Adial Pharmaceuticals, down from $164658.0 in the prior quarter.
  • Across five years, Revenue topped out at $164658.0 in Q1 2024 and bottomed at -$37901.0 in Q2 2023.
  • The 3-year median for Revenue is $5115.0 (2022), against an average of $29352.6.
  • The largest YoY upside for Revenue was 1005.68% in 2024 against a maximum downside of 100.0% in 2024.
  • A 3-year view of Revenue shows it stood at $5115.0 in 2022, then tumbled by 840.98% to -$37901.0 in 2023, then skyrocketed by 100.0% to -$1.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Revenue are -$1.0 (Q2 2024), $164658.0 (Q1 2024), and -$37901.0 (Q2 2023).